Radio
Now Playing
Quickyla Radio — Click to play
Open →
Radio
Now Playing Quickyla Radio — Click to play
Open Radio →
Breaking
MINDY3: A hub between protein quality control and DNA repairIntellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside AheadThis Stock Is Up 58% This Year. Is It too Late to Buy?The wrong prescription for drug affordability

Choose Language

Select a language for news translation.

Results for "biotech" 18 articles
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
📈 Markets & Finance
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?

Written by Robert Izquierdo for The Motley Fool -> Chief People Officer Francis Lo disposed of 39,741 Common Stock shares on June 4, 2026, for a total transac…

Nasdaq News 11 days ago 16
The Download: “reprogramming” aging, and the hidden sense of interoception
💻 Technology Live
The Download: “reprogramming” aging, and the hidden sense of interoception

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Why “reprogramming” i…

MIT Tech Review 14 days ago 15
Why “reprogramming” is the buzziest approach to reversing aging right now
💻 Technology Live
Why “reprogramming” is the buzziest approach to reversing aging right now

Earlier this week, Life Biosciences, a biotech company focused on reversing age-related diseases, announced that it had dosed its first volunteer. A person wit…

MIT Tech Review 14 days ago 8
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
📈 Markets & Finance Live
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?

Written by Adria Cimino for The Motley Fool -> Parabilis and another recent IPO stock each raised more than Moderna -- which had previously been the biggest b…

Nasdaq News 14 days ago 30
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?
📈 Markets & Finance Live
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?

Written by James Brumley for The Motley Fool -> The biotech has won approval for one of the few gene-editing therapies on the market. Several more therapies …

Nasdaq News 17 days ago 27
Best Biotech Stocks Right Now
📈 Markets & Finance Live
Best Biotech Stocks Right Now

The post Best Biotech Stocks Right Now by Chetan Shekar appeared first on Benzinga . Visit Benzinga to get more great content like this. Biotech stocks are in …

Benzinga 22 days ago 35
Alnylam, Inceptive Ink AI Drug Development Deal Worth Up To $2 Bln
📈 Markets & Finance Live
Alnylam, Inceptive Ink AI Drug Development Deal Worth Up To $2 Bln

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced partnership with Inceptive Nucleics, Inc., an artificial intelligence-driven biotechnology company, …

Nasdaq News 22 days ago 36
RNA 'cut-and-patch' tool repairs faulty messages without altering DNA
🔬 Science Live
RNA 'cut-and-patch' tool repairs faulty messages without altering DNA

A research team from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has achieved a significant advance…

Phys.org 24 days ago 32
Putin's quest to avoid the grim reaper: What’s behind the $26 Billion longevity programme?
🔬 Science
Putin's quest to avoid the grim reaper: What’s behind the $26 Billion longevity programme?

Putin launched a $26 billion longevity programme to boost Russia’s average life expectancy (currently 71 years) and address demographic decline through investm…

France 24 26 days ago 86
Markets
S&P 5005,432.18▲ 0.42%
NASDAQ17,891.40▲ 0.87%
DOW39,118.86▼ 0.15%
BTC$67,842▲ 2.14%
ETH$3,291▲ 1.38%
GOLD$2,341/oz▼ 0.31%
OIL (WTI)$82.14▲ 0.67%
EUR/USD1.0842▼ 0.09%
GBP/USD1.2641▲ 0.22%
NIKKEI38,471▲ 1.02%
FTSE 1008,218▼ 0.28%
Full Markets →
Local Weather
—°F
Local area
58% 12 mphH:78° L:61°
Emergency Alerts
Wildfire Warning — Northern California coastal counties until 8PM
High surf advisory — Bay Area beaches through the weekend
View all alerts →
✦ AI Powered
Summarize any article instantly
Get 30-second summaries, bullet points, deep analysis, or a child-friendly version — powered by AI.
30-sec summary Bullet points Deep analysis
✦ Based on Your Interests
Trending stories you might like
Sign in to personalize
Around the World
▶ Video News
🏥 Health
10 hours ago
Moderna stock doubles in 2024, cancer vaccine trial nears August FDA decision
Nasdaq News · ▶ Watch
🔬 Science
4 days ago
MINDY3: A hub between protein quality control and DNA repair
Phys.org · ▶ Watch
📈 Markets & Finance
5 days ago
Weight loss without muscle loss? The next generation of drugs is testing the idea
Business Insider Mkt · ▶ Watch
📈 Markets & Finance
6 days ago
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Nasdaq News · ▶ Watch
📈 Markets & Finance
8 days ago
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead
Nasdaq News · ▶ Watch
📈 Markets & Finance
9 days ago
This Stock Is Up 58% This Year. Is It too Late to Buy?
Nasdaq News · ▶ Watch
🏛️ Politics
10 days ago
The wrong prescription for drug affordability
The Hill · ▶ Watch
📈 Markets & Finance
10 days ago
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Nasdaq News · ▶ Watch
🔬 Science
10 days ago
Fred Ramsdell
Scientific American · ▶ Watch
📈 Markets & Finance
11 days ago
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
Nasdaq News · ▶ Watch
💻 Technology
14 days ago
The Download: “reprogramming” aging, and the hidden sense of interoception
MIT Tech Review · ▶ Watch
💻 Technology
14 days ago
Why “reprogramming” is the buzziest approach to reversing aging right now
MIT Tech Review · ▶ Watch
📈 Markets & Finance
14 days ago
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
Nasdaq News · ▶ Watch
📈 Markets & Finance
17 days ago
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?
Nasdaq News · ▶ Watch
📈 Markets & Finance
22 days ago
Best Biotech Stocks Right Now
Benzinga · ▶ Watch
📈 Markets & Finance
22 days ago
Alnylam, Inceptive Ink AI Drug Development Deal Worth Up To $2 Bln
Nasdaq News · ▶ Watch
🔬 Science
24 days ago
RNA 'cut-and-patch' tool repairs faulty messages without altering DNA
Phys.org · ▶ Watch
🔬 Science
26 days ago
Putin's quest to avoid the grim reaper: What’s behind the $26 Billion longevity programme?
France 24 · ▶ Watch
Religion & Culture More →
Islam Christianity Hinduism Judaism Sikhism Interfaith Culture

More to Read

This Stock Has Already Doubled This Year and Is Still Racin…
🏥 Health
Moderna stock doubles in 2024, cancer vaccine trial nears August FDA decision
Nasdaq News · 10 hours ago
MINDY3: A hub between protein quality control and DNA repair
🔬 Science
MINDY3: A hub between protein quality control and DNA repair
Phys.org · 4 days ago
Weight loss without muscle loss? The next generation of dru…
📈 Markets & Finance
Weight loss without muscle loss? The next generation of drugs is testing the id…
Business Insider Mkt · 5 days ago
Intellia Therapeutics vs. Omeros: Which Emerging Biotech St…
📈 Markets & Finance
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy …
Nasdaq News · 6 days ago
These 3 Stocks Have Crushed the Market This Year. Here's Wh…
📈 Markets & Finance
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upsi…
Nasdaq News · 8 days ago
This Stock Is Up 58% This Year. Is It too Late to Buy?
📈 Markets & Finance
This Stock Is Up 58% This Year. Is It too Late to Buy?
Nasdaq News · 9 days ago
The wrong prescription for drug affordability
🏛️ Politics
The wrong prescription for drug affordability
The Hill · 10 days ago
3 Under-the-Radar Stocks to Buy and Hold for a Decade
📈 Markets & Finance
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Nasdaq News · 10 days ago
Fred Ramsdell
🔬 Science
Fred Ramsdell
Scientific American · 10 days ago
What Does an Adaptive Biotech Insider's Sale of Nearly 40,0…
📈 Markets & Finance
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for I…
Nasdaq News · 11 days ago
The Download: “reprogramming” aging, and the hidden sense o…
💻 Technology
The Download: “reprogramming” aging, and the hidden sense of interoception
MIT Tech Review · 14 days ago
Why “reprogramming” is the buzziest approach to reversing a…
💻 Technology
Why “reprogramming” is the buzziest approach to reversing aging right now
MIT Tech Review · 14 days ago
Parabilis Soared 58% in the Biggest Biotech IPO on Record. …
📈 Markets & Finance
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Bu…
Nasdaq News · 14 days ago
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approve…
📈 Markets & Finance
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its S…
Nasdaq News · 17 days ago
Best Biotech Stocks Right Now
📈 Markets & Finance
Best Biotech Stocks Right Now
Benzinga · 22 days ago
Alnylam, Inceptive Ink AI Drug Development Deal Worth Up To…
📈 Markets & Finance
Alnylam, Inceptive Ink AI Drug Development Deal Worth Up To $2 Bln
Nasdaq News · 22 days ago
RNA 'cut-and-patch' tool repairs faulty messages without al…
🔬 Science
RNA 'cut-and-patch' tool repairs faulty messages without altering DNA
Phys.org · 24 days ago
Putin's quest to avoid the grim reaper: What’s behind the $…
🔬 Science
Putin's quest to avoid the grim reaper: What’s behind the $26 Billion longevity…
France 24 · 26 days ago
Full view